Charles Heine

Skip to main content All experts

PRG DIR & RES ASO PROF

MD-MEDICINE

Orcid identifier0009-0002-4746-4892 (opens in a new tab)⁠

PRG DIR & RES ASO PROF
MD-MEDICINE

henry.heine@medicine.ufl.edu (opens in a new tab)

sort by:

GRANT
Proof of Concept Post-exposure Prophylaxis (PEP) Efficacy with PK Endpoints in the Mouse Models of Inhalational Biothreat Agents
Biomedical Advanced Research & Devlpmt Author30 May 2025 - 31 Mar 2027
Active
GRANT
Proof-of-Concept Treatment (Tx) Efficacy in the Mouse Models of Inhalational Biothreat Agents
Biomedical Advanced Research & Devlpmt Author30 May 2025 - 31 Mar 2027
Active
GRANT
In vitro microbiological evaluation of Acurx DNA pol IIIC compounds against Category A Bacterial pathogens (B. anthracis)
Acurx Pharmaceuticals13 Aug 2024 - 15 Sep 2024
Expired
GRANT
Batelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
Defense Threat Reduction Agency18 Jul 2024 - 31 Dec 2024
Expired
GRANT
In Vitro Microbiological Evaluations of Delafloxacin Against Category A and B Bacterial Pathogen Panels
Biomedical Advanced Research & Devlpmt Author17 Nov 2023 - 28 Mar 2024
Expired
GRANT
In vitro testing of 100 isolates of B. pseudomallei
Biomedical Advanced Research & Devlpmt Author5 Sep 2023 - 31 Dec 2025
Expired
GRANT
Battelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
Defense Threat Reduction Agency17 Oct 2022 - 31 Dec 2026
Active
GRANT
In Vitro Microbiological Evaluations of Antibody-Drug Conjugates (ADCs) Against Category A and B Bacterial Pathogen Panels
National Institute of Health Niaid14 Apr 2022 - 31 Mar 2024
Expired
GRANT
Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4
Nabriva Therapeutics4 Mar 2022 - 30 Jun 2022
Expired
GRANT
In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels
Prokaryotics11 Jan 2022 - 31 Mar 2022
Expired
GRANT
Merck Study Agreement
Merck Sharp & Dohme4 Jan 2022 - 1 Jul 2023
Expired
GRANT
In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens
Nabriva Therapeutics2 Aug 2021 - 1 Aug 2022
Expired
GRANT
Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei
Defense Threat Reduction Agency24 Mar 2021 - 1 Apr 2027
Active
GRANT
Teixobactin Development for Anthrax
National Institute of Health Niaid22 Jan 2021 - 31 May 2021
Expired
GRANT
Evaluation of air purification methods for SARS-CoV-2
Helen of Troy12 Jan 2021 - 30 Jun 2021
Expired
GRANT
Project Bioshield
1 Nov 2020 - 31 Dec 2021
Expired
GRANT
MICs for Wockhardt WCK-5222
Wockhardt Bio Agriculture29 Oct 2020 - 26 Nov 2020
Expired
GRANT
Battelle Subcontract 778380 SAB Year 1
Defense Threat Reduction Agency15 May 2020 - 30 Sep 2024
Expired
GRANT
KBP Biosciences Research Agreement - In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens
*kbp Biosciences USA11 May 2020 - 10 Jul 2020
Expired
GRANT
Evaluation of antimicrobial peptides for Biodefense
Defense Threat Reduction Agency31 Mar 2020 - 30 Sep 2022
Expired
GRANT
EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study
Defense Threat Reduction Agency22 May 2019 - 10 Aug 2019
Expired
GRANT
EPDG-15-GC072-S-0001 Task 4.7 PK Study
Defense Threat Reduction Agency22 May 2019 - 10 Aug 2019
Expired
GRANT
In vitro testing of the 40 isolate panel of B. pseudomallei isolates
Defense Threat Reduction Agency16 Jan 2019 - 31 Oct 2020
Expired
GRANT
In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens
National Institute of Health Niaid29 Oct 2018 - 8 Apr 2019
Expired
GRANT
Confirmatory Efficacy Study in Bp Infected Mice
Defense Threat Reduction Agency28 Jun 2018 - 31 Mar 2019
Expired

GRANTS